Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Chromatography Resin Market to Register a Stout Growth by 2027-End: While other players in the global chromatography resin market have contributed around US$ 200 Mn, the top five players in the market such as Bio-Rad Laboratories, Inc., GE Healthcare, Tosoh Corporation, Merck KGaA, and Thermo Fisher Scientific Inc. hold more than 70% of the revenue share with a contribution of more than US$ 500 Mn in the global chromatography resin market in 2016.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/23/2018 | 12:14am CEST

Albany, NY -- (SBWIRE) -- 05/22/2018 -- Top five key players accounted for more than 70% revenue share of the global chromatography resin market in 2016

While other players in the global chromatography resin market have contributed around US$ 200 Mn, the top five players in the market such as Bio-Rad Laboratories, Inc., GE Healthcare, Tosoh Corporation, Merck KGaA, and Thermo Fisher Scientific Inc. hold more than 70% of the revenue share with a contribution of more than US$ 500 Mn in the global chromatography resin market in 2016. The remaining players contributed approximately 30% revenue share to the global chromatography resin market in 2016.

Currently, more than 60% revenue contribution comes from Tier 1 players, while Tier 2 players contribute more than 10% and Tier 3 players contribute about 25%. The U.S. based GE Healthcare alone has contributed more than 40% revenue share followed by other key players in the global chromatography resin market.

Stringent rules and regulations accompanied by available alternatives to chromatography are hampering revenue growth of the technology segment in the global chromatography market

Stringent rules and regulations laid down by the U.S. Food and Drug Administration and the European Commission for new products such as chromatography columns and resins for diagnostics and analysis purposes may hinder the growth of the technology segment of the global chromatography resin market. Besides, the regulations laid down by the regional authorities for the use of chromatography technologies may also restrain the growth of the overall market during the period of assessment.

Cost is another limiting factor. Higher selling price of resins is anticipated to restrict market growth to a great extent. Column chromatography is usually regarded as a major cost driver. Besides, for the fixed costs, the column membranes that are used for the purification of the proteins swallow a large proportion of the costs. This factor is likely to hamper the growth of the chromatography resin market during the forecast period.

Get a free sample request @ https://www.xploremr.com/connectus/sample/818

Repeated use of chromatography is another reason which is obstructing the growth of the by technology segment over the projected period. For the low-cost manufacturing of bio pharmaceuticals in the developing countries, several tactics are followed to reduce the costs such as repeated use of chromatography column resins during the purification process often stretching their use for more than 100–200 cycles which in turn affects the overall by technology segment. Further, many industries use a smaller protein A column instead of using a large ProteinA column and multiple cycles are performed for the single batch of mABs. This also affects the segment.

Increasing production of monoclonal antibody through affinity chromatography is expected to fuel market growth

The affinity chromatography segment by technology dominated the global chromatography resin market in revenue terms in 2016 and the trend is projected to continue throughout the forecast period. The affinity chromatography segment is anticipated to be the most lucrative among all technologies, with a market attractiveness index of 1.9. Projected to reach a market valuation in excess of US$ 650 Mn by the end of 2027 from an estimated US$ 279 Mn in 2017, the affinity chromatography segment is slated to witness a substantial CAGR of 9.3% in terms of value during the period 2017-2027.

Buy Now Full Report @ https://www.xploremr.com/cart/reports/buynow/818

For more information on this press release visit: http://www.sbwire.com/press-releases/chromatography-resin-market-to-register-a-stout-growth-by-2027-end-981521.htm

Media Relations Contact

Abhishek Budholiya
Consultant
Xplore Market Research
Telephone: 1-866-997-4948
Email: Click to Email Abhishek Budholiya
Web: https://www.xploremr.com

© ReleaseWire, source Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA 1.98% 85.36 Delayed Quote.-7.32%
THERMO FISHER SCIENTIFIC -1.07% 213.65 Delayed Quote.14.03%
TOSOH CORPORATION 0.83% 1944 End-of-day quote.-24.80%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
05/23CHROMATOGRAPHY RESIN MARKET TO REGIS : While other players in the global chromat..
AQ
05/22MERCK : Darmstadt, Germany, Ignites Firework of Research Initiatives During its ..
PU
05/22MERCK : Darmstadt, Germany, Survey Reveals Most Thyroid Disorder Patients Find R..
PU
05/17MERCK : Researchers from Merck KGaA Report on Findings in Zika Virus (Mitigating..
AQ
05/17Merck, Pfizer report early data for PD-L1/ALK inhibitor combos
AQ
05/16MERCK : MilliporeSigma to Use Genome Editing in Study of Gut Bacteria to Benefit..
PU
05/15MERCK KGAA : to Host Earnings Call
AQ
05/15MERCK KGAA : to Host Earnings Call
AC
05/15Merck KGaA's Shares Fall After 1Q Results -- Update
DJ
05/15Merck KGaA's 1Q Sales Decline, Dragged by Currency Headwinds
DJ
More news
News from SeekingAlpha
05/23MERCK KG&A (MKGAY) Presents At 2018 UBS Global Healthcare Conference - Slides.. 
05/15Merck's (MKGAF) Management on Q1 2018 Results - Earnings Call Transcript 
05/15Merck KGaA 2018 Q1 - Results - Earnings Call Slides 
05/15Merck KGaA reports Q1 results 
05/02Merck KGaA to develop abituzumab for CRC with SFJ 
Financials (€)
Sales 2018 15 050 M
EBIT 2018 2 940 M
Net income 2018 1 974 M
Debt 2018 7 866 M
Yield 2018 1,51%
P/E ratio 2018 17,80
P/E ratio 2019 17,38
EV / Sales 2018 1,24x
EV / Sales 2019 1,08x
Capitalization 10 818 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 96,8 €
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-7.32%12 665
ABBVIE6.65%163 671
KYOWA HAKKO KIRIN CO LTD1.13%11 958
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD80.22%11 098
JAZZ PHARMACEUTICALS PLC24.09%9 815
CONVATEC GROUP10.02%5 929